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Abstract
Background: The aim of this study was to determine the clinical benefit of transhepatic arterial chemoembolization
(TACE) with or without recombinant human adenovirus type 5 (H101) administration for the treatment of patients with
hepatocellular carcinoma (HCC).
Methods: Tumor response, progression-free survival (PFS), and overall survival(OS) were retrospectively evaluated
in consecutive patients with unresectable HCC who received TACE with or without H101 between April 2012 and
April 2013.
Results: Patients with unresectable HCC were treated with transarterial injection of H101 with TACE (H101 group,
n = 87) or TACE alone (control group, n = 88). Clinicopathological features were similar between the groups. Treatment
response was significantly different between the groups (P = 0.01). In the H101 group, 25 patients demonstrated a
complete response (CR, 28.7 %); 28 patients, a partial response (PR, 32.2 %); 23 patients, stable disease (SD, 26.4 %);
and 11 patients, progressive disease (PD, 12.6 %). In the control group, 13 patients demonstrated CR (14.8 %); 19,
PR (21.6 %); 34, SD (38.6 %); and 22, PD (25 %). OS and PFS was also significantly different between the groups. In
the H101 group, median OS and PFS were 12.8 and 10.49 months, whereas in the control group they were 11.6
and 9.72 months, respectively (OS: P = 0.046; PFS: P = 0.044).
Conclusion: In patients with unresectable HCC, H101 combined with TACE improves OS, PFS and treatment response
compared with TACE alone.
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Background
Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer-related death worldwide [1]. Less
than 20 % of patients with HCC are eligible for poten-
tially curative liver transplantation or surgical resection
[2]. Worldwide, transhepatic arterial chemoemboliza-
tion (TACE) is regarded as the best palliative treatment
for unresectable HCC and has been shown to provide a
clinical survival benefit [2], albeit with poor prognosis
[3] suggesting that additional strategies are needed to
improve patient prognosis.
Gene therapy, especially oncolytic viral therapy, is a
promising treatment for liver tumors and is being increas-
ingly used in the clinic with favorable results [4]. H101 is a
recombinant human type-5 adenovirus (Ad5) in which the
gene encoding the 55 kDa E1B protein responsible for
p53-binding and inactivation has been deleted to confer
p53-selective replication of oncolytic viruses inducing
accumulation of p53 leading to direct and selective
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cytotoxicity in tumor cells during replication [5]. The
H101 virus produced by Shanghai Sunway Biotech also
contains a deletion of a 78.3–85.8 μm gene segment in
the E3 region. The E3 region is responsible for the in-
hibition of host immunity, which enhances virus repli-
cation and spread in tumor cells [6].
Previous studies evaluating the safety of H101 as a direct
injection [7] or transarterial infusion combined with TACE
[8, 9], but the result were insufficient because of the small
patient numbers (10,27,1), moreover, without a control
group. While this large sample-sized study has enrolled 87
patients treated by H101 with a control group(n = 88),
aimed to demonstrate the effect for unresectable HCCs.
In the current study, treatment-related tumor response,
overall survival(OS) and progression free survival (PFS)
rates between H101 plus TACE and TACE alone were
compared as the primary endpoints. The secondary end-




This retrospective study was approved by the ethics com-
mittee of Sun Yat-Sen University Cancer Center, and was
performed in accordance with the Helsinki Declaration of
1975, as revised in 1983. From April 2012 to April 2013,
367 consecutive patients with unresectable HCC who
underwent TACE, with or without transarterial injection
of H101, at the Sun Yat-Sen University Cancer Center
were enrolled. The diagnosis of HCC was based on non-
invasive criteria according to the recommendation of the
European Association for the Study of the Liver (EASL)
and the European Organization for Research and Treat-
ment of Cancer (EORTC) [10]. The definition of surgical
unresectability was as follows: (1) Child-Pugh classification
B; (2) ≥3 tumor nodules of any size; and (3) the inability to
ensure adequate function of the postresection liver vol-
ume. Eligibility criteria included: (1) no previous treatment
for HCC before TACE; (2) adequate hematological func-
tion (Child-Pugh A or Child-Pugh B); (3) adequate renal
function (serum creatinine < 140 μmol/L, and serum blood
urea nitrogen < the upper limit of normal). Exclusion cri-
teria included: (1) previous resection or ablation before
TACE, (2) prior bland embolization; and (3) if the patient
had received therapy with more than one type of embolic
agent or transcatheter therapy. Patients who met the cri-
teria provided written informed consent for the study.
Treatment procedures
For each modality, a uniform treatment protocol was
followed. TACE was performed through the femoral artery
with use of the Seldinger technique with local anesthesia as
previously reported [11]. The chemotherapeutic agents
were infused into the hepatic artery supplying the tumor(s).
Conventional chemoembolization was performed by ad-
ministering carboplatin 300 mg (Bristol-Myers Squibb,
NY, USA). Thereafter, chemolipiodolization was per-
formed using epirubicin 50 mg (Pharmorubicin, Pfizer,
Wuxi, China), and mitomycin 6 mg (Zhejiang Hisun
Pharmaceutical Co. Ltd., Taizhou, China) mixed with
5 mL of lipiodol (Lipiodol Ultra-Fluide; Andre Guerbet
Laboratories, France).
H101 was administered via the catheter into the hepatic
artery supplying the tumor(s). A total of 1.0 × 1012 virus
particles in 10 mL 0.9 % sodium chloride were adminis-
tered. Sterile purified viral lots were produced for human
clinical use by Shanghai Sunway Biotech (Shanghai, China),
and tested for the titer, sterility, and general safety by the
National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, China).
Follow-up
Antitumor efficacy was evaluated by computed tomog-
raphy/magnetic resonance imaging (CT/MRI) at 1 month
post-treatment and every 3–4 months thereafter. Further
treatments were based on clinical evaluation, laboratory
values, and imaging response. Tumor response accord-
ing to the modified Response Evaluation Criteria in Solid
Tumors (mRECIST) guidelines [12] was independently
assessed in a blinded manner by 3 qualified radiologists.
When a difference of opinion occurred, a consensus was
obtained through discussion.
Liver function tests, ascites, and encephalopathy were
monitored during follow-up visits to assess for liver fail-
ure. Clinical AEs were graded according to the National
Cancer Institute (NCI) Common Terminology Criteria
for Adverse Events (CTCAE) v4.0 criteria [13].
Statistical analysis
The statistical significance of the difference between the
means of continuous variables was determined using the
independent t-test. A P-value of 0.05 was considered to
be statistically significant. The chi-squared test was used
to compare categorical variables. The Kaplan–Meier
method was used to estimate OS and PFS.
Results
Patient demographics and clinical characteristics were similar
between the groups and are shown in Table 1. From April
2012 to April 2013, 187 patients with unresectable HCC were
treated withTACE plus H101 met the inclusion criteria (H101
group) (Additional file 1: Figure S1) . In the same period, 88
patients with unresectable HCC underwent conventional
TACE alone met the inclusion criteria (control group).
Tumor response is shown in Table 2 significant differ-
ence was noted in tumor response between the two
groups (Table 2). Furthermore, subgroup analysis accord-
ing to treatment response showed that the number of each
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Table 1 Patient demographics and characteristics
Overall H101 Control P-Value Overall
Survival(%)
Median survival(mo) Univariate Multivariate
1-yr 2-yr P-Value ExpB (Hazard
Ratio ,95 % CI)
P-Value
Gender 0.305 0.302
Male 159 81 78 67 52 13.0
Female 16 6 10 60 30 11.2
Age 0.948 0.100
Median 55.0 55.0 54.5
< 60 114 59 55 68 49 12.5
≥ 60 61 28 33 68 56 13.0
Alpha-foetoprotein(ng/ml) 0.316
307.2 269.1 307.2
Alpha-foetoprotein(ng/ml) 0.947 0.06 1.669(1.178–2.366) 0.004
≤ 20 53(30.1 %) 27(30.7) 26(29.5) 89 81 17.6
20–400 42(23.9 %) 20(22.7) 22(25.0) 60 45 13.9
≥ 400 80(45.5 %) 40(45.5) 40(45.5) 52 32 9.1
Child Pugh grade 0.820 0.007 2.132(1.138–3.995) 0.018
A 154(88.0 %) 76(87.3 %) 78(88.6 %) 70 55 13.3
B 21(12.0 %) 11(12.6) 10(11.3) 38 25 7.7
ALB(g/L) 0.228 0.412
Median 40.0 39.6 40.2
≥ 35 131 61 70 0.166 62 50 11.7
< 35 44 26 18 67 52 13.3
Tbil(U/L) 0.386 0.003
Median 16.4 16.1 16.8
< 20 119 61 58 0.628 75 56 13.7
≥ 20 56 26 30 48 40 8.0
Virus infection 0.970 0.101
none 15 7 8 88 66 13.6
HBV 158 79 79 63 51 12.6
HCV 2 1 1 50 0 13.9
Platelet count (10E9/L) 0.630 0.676
Median 167.0 179.2 154.5
< 100 31 11 20 0.112 63 46 12.2 0.330(0.141–0.773) 0.011
≥ 100 144 76 68 67 53 12.8
No. of tumours 1.000 <0.001 2.024(1.127–3.633) 0.018
≤ 3 127 69 70 74 57 13.7
> 3 36 18 18 38 30 7.6
Tumour size (cm) 0.730 0.028 2.936(1.297–6.650) 0.010
≤ 5 45 21 24 91 75 18.1
> 5 130 66 64 56 42 9.8
Anti-HBV therapy 0.197 0.424
Yes 56 32 24 60 54 13.3
No 119 55 64 69 51 9.65
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response type was significantly different between the
groups (Table 2). In general, patients in the H101 group
responded better to treatment compared with those who
received TACE alone.
The majority of the patients (90.2 %) tested positive
for hepatitis B virus (HBV) and some patients received
anti-HBV agents that could potentially confound the
beneficial effects of H101 as antiviral agents. To deter-
mine the effect of anti-HBV treatment on H101, patients
were stratified by anti-HBV therapy administration. As
shown in Table 2B, there was no significant difference in
treatment response between the two subgroups.
Significant positive correlations have been reported be-
tween lipiodol accumulation observed on CT images and
necrosis in resected tumors examined after TACE, and,
therefore, intratumor lipiodol accumulation is regarded as
an indicator of necrosis [14, 15]. The degree of lipiodol re-
tention for all patients is presented in Table 3. There were
significant differences in lipiodol accumulation between
the two treatment groups (P = 0.002).
Blood samples for laboratory analysis were collected before
and 1–2 days after TACE for each patient (Table 4). There
were no significant differences in clinical parameters between
the two groups with the exception of a significant increase in
white blood cell count in the H101 group compared with the
control group (P= 0.001). Post-treatment AEs are shown in
Table 4 Fever was significantly higher in the H101 group
compared with the control group (P= 0.023). No grade 4
clinical toxicity or procedure-related deaths (30 days) due to
liver failure were experienced in either group. There were no
major complications or grade 3–4 liver toxicities within the
first post-treatment month. The overall frequency of
treatment-emergent AEs was not significantly different
between the groups (P= 0.263).
The median OS time during follow-up was 12.8 months
(mean ± SD: 12.95 ± 8.36 months) in the H101 group and
11.6 months (mean ± SD: 12.87 ± 8.28 months) in the con-
trol group. 24 patients (27.6 %) in the H101 group and 41
(46.6 %) in the control group expired. The causes of death
included liver disease progression (46/65, 70.8 %), upper
gastrointestinal hemorrhage (7/65, 10.8 %), encephalopathy
(7/65, 10.8 %), and peritonitis and pneumonia (6/65,
9.2 %). There were no treatment-related deaths. The cumu-
lative OS rates at 1 and 2 years were significantly different
and were 69 and 60 % in the H101 group, respectively, 60
and 44 % in the control group, respectively (P = 0.046, Fig.
1). Univariate analysis by Cox-regression revealed 6
prognostic factors affecting OS: Child-Pugh grade (grade A
vs. grade B, P = 0.007), total bilirubin (<20 vs. ≥20 U/
L, P = 0.003), BCLC(Barcelona Clinic Liver Cancer
)stage (P = 0.001), tumor number (≤3 vs. >3, P <
0.001), tumor size (≤5 cm vs. >5 cm, P = 0.028), and
H101 (P = 0.042). Multivariate analysis by cox-
regression revealed that AFP (P = 0.004), CHILD
PUGH grade (P= 0.018), BCLC stage(P= 0.002), Platelet
count (PLT)(P= 0.011), the number of tumors (P= 0.018),
tumor size(P= 0.010)and H101 (P= 0.048) were independent
prognostic factors of OS.
After the first post-treatment review, all 175 patients
were assigned as CR, PR, SD, or PD according to
Table 1 Patient demographics and characteristics (Continued)
H101 0.046 0.042 0.593(0.353–0.995) 0.048
Yes 87 87 0 69 60 12.8
No 88 0 88 60 44 11.6
BCLC stage 0.453 0.001 2.168(1.322–3.557) 0.002
A3 1 0 1
A4 17 10 7 94 94 17.0
B 108 50 58 72 56 12.96
C 49 27 22 52 23 6.96
AFP alpha fetoprotein, ALB serum albumin, HBV hepatitis B virus, HCV hepatitis C virus, TBIL total bilirubin, PVT portal vein thrombosis
Table 2 Treatment response of H101 group and control group
Overall H101(none + Anti-HBV Therapy,P = 0.162) Control P value
0.010
CR 38(21.7 %) 25 (28.7 %)(16 + 9) 13(14.8 %) 0.017
PR 47(26.9 %) 28(32.2 %)(21 + 7) 19(21.6 %) 0.172
SD 57(32.6 %) 23(26.4 %)(14 + 9) 34(38.6 %) 0.107
PD 33(18.9 %) 11(12.6 %)(4 + 7) 22(25 %) 0.011
All patients enrolled in H101 group were screened to sort out cases with anti-HBV therapy or without anti-HBV therapy.
None: Patients treated by H101 without anti-HBV therapy.
Anti-HBV Therapy: Patients treated by H101 with anti-HBV therapy session.
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mRECIST criteria. In total, 142 patients in both groups
(H101: 74; control: 68) were judged as CR, PR, or SD.
During follow-up, progression free survival was observed
in these 142 patients. The median time to progression for
the H101 and control groups were significantly different
at 10.49 and 9.72 months, respectively (P = 0.044, Fig. 2).
In univariate analysis by cox-regression, 3 prognostic fac-
tors affecting tumor progression were identified: tumor
number (P = 0.002), tumor size (P = 0.041), and treatment
modality (H101; P = 0.036; Table 5). Multivariate analysis
identified 4 prognostic factors as independent predictors of
progression: the number of tumors (P = 0.001), tumor size
(P = 0.041), Child-Pugh grade (P = 0.050) and treatment
modality (H101) (P = 0.017, Table 5).
Discussion
The main purpose of this study was to compare the out-
comes of patients with late stage HCC treated with two
different methods of chemoembolization: a conventional
method with commonly used protocols, and one using
H101 virus. The data revealed that transcatheter therapy
with H101 provided a significant tumor response and
survival advantage over treatment with conventional
chemoembolization (TACE alone) in patients with unre-
sectable HCC.
H101 is an E1B-55 K-/E3B-deleted adenovirus [16],
which has been used as an anticancer agent with the
goal of restricting replication to p53-mutated neo-
plasm, sparing p53 wild-type human tissues. Preclinical
studies have confirmed the anticancer activity of the
H101 virus [17]. Clinical studies demonstrated the tol-
erability and anti-tumor efficacy of this agent as a
monotherapy in patients with head and neck cancer
[18, 19]. Different studies have compared the efficacy
and safety of multiple routes of H101 administration in
patients with HCC or liver tumors including hepatic ar-
terial administration [20, 21],intravenous injection, and
ultrasound-guided intratumoral injection [7, 22, 23].
Overall, H101 was safe when administered intratumo-
rally, intraperitoneally, intraarterially, or intravenously
at doses up to 3 × 1011 pfu [8, 24].
In this study, a significant difference in response rate
was noted between the H101 and control groups. Radio-
logically, tumor response as determined by mRECIST
Table 4 Clinical adverse effects
Overall H101 Control P value
Fever 0.023
> 38.5 °C 55.4 % 64.4 % 46.6 %
≤ 38.5 °C 44.6 % 35.6 % 53.4 %
Pain 0.875
Yes 65.1 % 64.4 % 65.9 %
No 34.9 % 35.6 % 34.1 %
Ascites 0.864
Yes 25.7 % 26.4 % 25 %
No 74.3 % 73.6 % 75 %
Acute renal failure
Yes 5.1 % 5.7 % 4.5 % 0.896
No 94.9 % 94.3 % 95.5 %
Encephalopathy
Yes 0 0 0
No 100 % 100 % 100 %
White Blood Cell
Before TACE 5.7 6.0 5.5 0.369
After TACE 7.64 7.0 8.84 0.991
Elevation 1.61 0.5 2.97 0.001
PLT
Before 167.0 179.2 154.5 0.186
After 113.0 122.8 106.1 0.258
Elevation 49.0 52.7 48.4 0.480
ALT
Before 41.5 43.2 41.4 0.371
After 167.1 153.0 200.9 0.405
Elevation 103.1 88.1 118.4 0.480
AST
Before 50.9 57.1 46.4 0.249
After 221.3 225.4 213.5 0.993
Elevation 154.2 141.2 162.0 0.863
TBIL
Before 16.3 16.1 16.8 0.657
After 30.4 28.3 31.8 0.162
Elevation 12.9 12.4 13.25 0.413
ALB
Before 40.0 38.2 41.2 0.161
After 35.4 34.1 37.0 0.314
Elevation 4.1 3.6 4.4 0.226
PLT platelet count, ALB albumin, ALT alanine aminotransferase, AST aspartate
aminotransferase, PLT platelet, TACE transhepatic arterial chemoembolization,
TBIL total bilirubin
Table 3 Tumor response
Overall H101 Control P value
Alpha-fetoprotein(ng/ml) reduce 0.448
≥ 20 % 77 41 36
< 20 % 98 46 52
Lipiodol retention 0.002
None 20 7 13
Partial 132 61 71
Complete 23 19 4
CR complete response, PR partial response, SD stable disease, PD
progressive disease
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was shown as obvious volume shrinkage and large areas of
necrosis in tumor. The response rate of the control group
was similar to that reported in previous studies of our de-
partment [25]. In the H101 group, greater improvements
were seen especially with regard to CR and PD which may
suggest more complete necrosis in the tumor and less
lost-control. The mechanism behind the increased efficacy
of H101 is not clear but may suggested as follows: 1)H101
is a p53-mutated specific agent, and up to 30–50 % [26]
HCCs were found mutated or lost of p53. 2) Pei et al. [27]
showed that HCC cells expressed high levels of inhibitor
of apoptosis proteins, and were resistant to tumor necrosis
factor (TNF)-related apoptosis while E1B-55 K-deleted
oncolytic adenovirus showed partial antitumoural efficacy
in the BEL7404 xenograft tumour model. 3)H101 has syn-
ergistic effect while combined with chemotherapy, and the
enhanced antitumor effect was demonstrated in Hep3B
(p53-null) and HepG2 (p53-wt) in vitro and in vivo [28].
The OS and PFS rate was significantly different between
the two treatment modalities, and results from cox-
regression showed H101 were the independent prognostic
factor for these late stage HCC patients. These results co-
ordinate with the response advantage of H101, demon-
strate the survival advantage for HCCs. However, as
generally accepted, beside tumor burden, overall survival
in unresectable HCCs is affected by multiple reasons. First,
OS in patients with HCC is greatly affected by the degree
of liver dysfunction, and patients with Child-Pugh B liver
Fig. 2 The Kaplan–Meier survival analysis for progression-free survival of the 74 patients with unresectable HCC who underwent TACE combined
with H101 and the 68 patients with unresectable HCC who underwent TACE alone.
Fig. 1 The Kaplan–Meier survival analysis comparing the overall survival from the first transcatheter therapy of advanced stage HCC patients who
underwent TACE combined with H101 (H101 group, n = 87) and TACE alone (control group, n = 88).
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function usually have poor survival regardless of the treat-
ment regimen [29]. In many cases, liver function did not
reflect the tumor response and in some patients liver func-
tion actually worsened with tumor shrinkage. In this study,
most patients had a liver function status graded as Child-
Pugh A(88 %), 21 Child-Pugh B cases were nearly even in
the two groups(10:11), the bias to overall survival was in-
significant. Second, TACE was the initial treatment for
these patients, most of whom received subsequent treat-
ments including resection, ablation, repeated TACE, and
Table 5 Univariate and Multivariate analysis of PFS
Cases Univariate Multivariate
1-yr survival rate(%) 2-yr survival rate(%) Median survival(mo) P-Value ExpB (Hazard Ratio ,95 % CI) P-Value
Gender
Male 130 47 26 10.79 0.331
Female 12 37 0 6.11
Age
< 60 92 49 29 10.49 0.180
≥ 60 50 40 21 9.35
Alpha-foetoprotein(ng/ml)
≤ 20 42 50 44 11.99 0.445
20–400 37 35 8 7.03
≥ 400 63 51 28 8.37
Child Pugh grade 0.047 2.852(1.002–8.293) 0.050
A 133 48 28 10.56
B 9 22 0 7.07
ALB(g/L) 0.307
≥ 35 108 46 20 10.49
< 35 34 47 47 10.25
Tbil(U/L) 0.429
< 20 104 49 23 11.18
≥ 20 38 37 32 6.21
Platelet count (10E9/L)
< 100 19 74 32 13.57 0.144
≥ 100 123 42 25 9.83
No. of tumours 0.034 3.992(1.978–8.057) 0.001
≤ 3 118 51 28 11.04
> 3 24 21 14 7.6
Tumour size (cm) 0.988 2.667(1.041–6.832) 0.041
≤ 5 35 39 24 11.37
> 5 107 48 25 8.37
Virus infection 0.079
none 14 59 59 13.05
HBV 126 43 24 10.25
HCV 2 50 0 11.30
Anti-virus therapy 0.951
Yes 33 44 30 8.37
No 95 43 22 10.56
H101 0.051 0.461(0.244–0.870) 0.017
Yes 74 51 32 10.49
No 68 41 20 9.72
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systemic therapies, or best supportive care. As our previous
prospective clinical trial demonstrated, subsequent treat-
ments can influence OS, especially for patients with large
and multiple HCC at diagnosis; surgical resection for pa-
tients who responded well to TACE significantly prolonged
survival, when compared to those who refused surgery
[30]. In this study, patients whose tumor was downstaged
were offered radical treatment including 36 patients for
surgical resection and 29 for local ablation, most of which
was CR, PR and some of SD, but without PD patient.
These subsequent treatments most likely improved OS,
which would enhance the advantage of tumor response.
More than 80 % of patients with HCC in Asia are hepa-
titis B virus positive, and most are receiving anti-viral ther-
apy [31]. This could confound the results of any evaluation
of H101 because it is a recombinant adenovirus and anti-
viral therapy has the potential to prevent H101 replication.
However, to the best of our knowledge, this has not been
previously investigated. The most employed anti-viral
agents for hepatitis B in our patients were lamivudine
(35.5 %), adefovir dipivoxil (14.7 %), and entecavir (42.3 %).
There are no reported studies demonstrating any potential
interaction of these agents with adenovirus. Moreover,
stratification of our patient data to those receiving anti-
viral therapy or not, did not reveal any significant effect of
antiviral therapy on H101 efficacy in terms of tumor re-
sponse or OS and PFS.
Other than efficacy, safety and adverse events are im-
portant aspects to consider in patients undergoing viral
therapy. The first case of a patient dying as a result of
gene therapy was reported in 1999 by Marshall [32]. The
patient, a relatively fit 18-year-old male with an inherited
enzyme deficiency, received a dose of 4 × 1013 pfu of a
replication-deficient adenovirus expressing the ornithine
transcarbamylase gene. Less than 24 h later, he experi-
enced hyperammonemia, acute respiratory distress syn-
drome, disseminated intravascular coagulation, and
suffered multiorgan system failure. He died 4 days later,
which questioned the safety of adenovirus for gene
therapy [33, 34]. However, subsequent studies have
found no mortality associated with adenoviral vector
therapy and any complications are usually mild and re-
versible [8, 35], suggesting that the case reported by
Marshall et al., may be a sporadic case of accidental death.
In this study, no patients died and all AEs were reversible.
The complication rates between H101 group and TACE
alone (control) group were similar. Child-Pugh class A
and B patients did not experience any major complications
after treatment with H101, but did experience liver failure
after treatment, but there was no statistically significant
difference in liver toxicity at 1–2 months between the
treatment groups. Increases in liver enzymes and total bili-
rubin levels and decreases in serum albumin levels were
mild and not significantly different between the treatment
groups. However, frequent high fever (P = 0.023) and an
increase in the white blood cell count (P = 0.001) were ap-
parent in the H101 group, which might be explained by
the immune activation. Previous studies have noted an in-
crease in inflammatory cytokine generation and fever after
hepatic arterial infusion of adenovirus [36]. Interestingly,
Lu et al., [36] found that during H101 injection, the effi-
cacy was significantly higher in those who had fever than
that in those who did not, suggesting that virus infection
may activate the host immune system and the elevated
cell-mediated immunity may play a role in the tumor re-
gression. In this study, subgroup analysis based on fever
did not reveal any differences between fever and treatment
efficacy (OS, P = 0.109; PFS, P = 0.221).
This study has several limitations including its retro-
spective nature. As a case-controlled study, the survival
benefit demonstrated must be considered preliminary
and further prospective, randomized-controlled, long-
term studies are needed to confirm our results.
Conclusion
Transcatheter H101 therapy in combination with TACE
for patients with unresectable HCC may provide a survi-
val(OS and PFS) and tumor response advantage over
treatment with conventional TACE alone.
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